

Long-Acting ADHD Medications - Availability and Claims Data

April 2024 Carrie Holden, Pharm.D



Amphetamine-Containing CNS Stimulants



Generic Name	Brand Name	Generic Available	How Supplied	Dosing	AZ	СТ	FL	T X	NY	Rejected Claim % (Jan 2023 – Mar 2024)
Amphetamine	Adzenys XR-ODT	N	 Extended-Release Disintegrating Tablets Extended-Release Suspension 	Once Every Morning	-	-	-	-	-	0
	Dyanavel XR	N	Extended Release TabletsExtended-Release Suspension	Once Every Morning	-	-	-	-	-	0
Dextro- Amphetamine	Xelstrym	N	Transdermal Patch	One Every 24 Hours	-	-	-	-	Y*	0
Amphetamine/ Dextroamphetamine	Adderall-XR	Y	Extended-Release Capsules	Once Every Morning	Y*	-	Y*	-	-	37.3%
	Mydayis	Y	Extended-Release Capsules	Once Every Morning	-	-	Y*	-	-	0.3%
Lis- Dexamfetamine	Vyvanse	Y	CapsulesChewable Tablets	Once Every Morning	-	-	-	-	-	27.9%
Meth- Amphetamine	Desoxyn	Y	Tablets	Once or Twice Daily	-	-	-	-	-	0

^{*}Dose/Forms Not Specified

Methylphenidate-Containing CNS Stimulants



Generic Name	Brand Name	Generic Available	How Supplied	Dosing	AZ	C T	FL	T X	NY	Rejected Claim% (Jan 2023 – Mar 2024)
	Aptensio XR	Y	Biphasic-Release Capsule	Once Every Morning	Y*	-	-	-	Y*	1.3%
Methylphenidate	Concerta/ Relexxi	Y	Extended-Release Tablet	Once Every Morning	Y*	-	-	-	Υ*	6.9%
	Jornay PM	N	Extended-Release Capsule	Once Every Morning	Y*	-	-	-	Υ*	0
	Qullichew ER	N	Extended-Release Chewable Tablet	Once Every Morning	Y*	-	-	-	Υ*	0
	Qullivant XR	N	Extended-Release Powder for Suspension	Once Every Morning	Y*	-	-	-	Υ*	0
	Ritalin	Y	Immediate Release TabletChewable TabletSolution	Two to Three Times Daily	Y*	-	-	-	Υ*	0
Serdexmethylphen/ Dexmethylphenidate	Azstarys	N	Capsules	Once Every Morning	-	-	-	-	-	0
Dexmethylphenidate	Focalin XR	Y	Extended Release Capsules	Once Every Morning	-	-	-	-	-	2.2%

^{*}Dose/Forms Not Specified

Norepinephrine Reuptake Inhibitors



Generic Name	Brand Name	Generic Available	How Supplied	Dosing	AZ	СТ	FL	TX	N Y	Rejected Claim % (Jan 2023 – Mar 2024)
Atomoxetine	Strattera	Y	Capsules	Once or Twice Daily	Υ	ı	Υ	-	-	22.9%
Viloxazine	Qelbree	N	Extended-Release Capsules	Once Daily	-	-	-	-	-	1.3%

Confidentiality Statement



By receipt of this material, each recipient agrees that the information contained herein will be kept confidential and will not be photocopied, reproduced or distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics and Magellan Rx.

The information contained in this presentation is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment. The information here should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.